Novavax says its vaccine is 89.3% effective in UK trial – Times of India
Novavax said the trial, which enrolled 15,000 people aged 18 to 84, is expected to be used to apply for regulatory review in Britain, the European Union and other countries. Some 27% of people in the trial are over 65.
The study took place as the more easily transmissible UK variant was circulating, and the preliminary analysis suggests the vaccine was 85.6% effective against this mutation, the U.S. company announced in a news release. It did not provide the study data.
Comments are closed.